Dr. Block is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
124 Tunbridge Cir
Haverford, PA 19041Phone+1 484-868-8909Fax+1 610-649-7522- Is this information wrong?
Summary
- Dr. Gilbert Block is a neurologist in Haverford, PA. He received his MD degree and PhD from Case Western Reserve University School of Medicine. He has been on the faculty of New York Hopsital- Cornell University Medical Center and University of Pennsylvania. He is an adjunct professor of pharmacology and physiology at Drexel Universtiy School of Medicine. He has > 34 years of biotecn and pharmaceutical expereince focusing on development of drugs neurologic, psychiatric and rare diseases with expereince across all phases of drug development as well as preclinical translational models. He has been responsible for or payed a critical roll in 9 successful NDAs and WMAs. He has consulted for venture capital companies, big pharma, and biotech. He has been a consultant for the Gladstone Institutes and NCATS at NIH. He is currently the Chief Mecial Officer of both Altpep and Reset Pharmaceuticals.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1982 - 1985
- New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1981 - 1982
- Case Western Reserve University School of MedicineClass of 1981
Certifications & Licensure
- PA State Medical License 1988 - 2000
Publications & Presentations
PubMed
- 65 citationsRandomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.Robert G. Miller, Gilbert Block, Jonathan S. Katz, Richard J. Barohn, Vidhya Gopalakrishnan, Merit Cudkowicz, Jane R. Zhang, Michael S. McGrath, Elizabeth Ludington, S...> ;Neurology(R) Neuroimmunology & Neuroinflammation. 2015 Jun 1
- A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ> ;Clin. Nephrol.. 2007-12-01
- 358 citationsA randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.Leon J. Thal, Steven H. Ferris, Louis Kirby, G. Block, Christopher R. Lines, Eric C. Yuen, Christopher Assaid, Michael L. Nessly, Barbara A. Norman, Christine C Barana...> ;Neuropsychopharmacology. 2005 Jun 1
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: